anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an animal depilating powdered soap, which belongs to a depilatory. The depilating powdered soap solves the problems of poor durability, poor stability, short expiration data, and inconvenient storage and transport in the current depilation products. The animal depilating powdered soap comprises the following raw materials in parts by weight: 10-50 parts of sodium aliphatate, 50-90 parts of anhydrous sodium sulfide, 3 parts of sodium hydroxide, 0.03-0.25 parts of disodium ethylene diamine tetraacetate, and 0.1-0.25 parts of 1-hydroxy ethylidene-1, 1-diphosphonic acid. A method of the powdered soap comprises the steps of production of a soap base, mixing, drying, addition of anhydrous sodium sulfide, crushing, and packaging to obtain a solid depilation preparation. The animal depilating powdered soap has the advantages of good durability, strong decontamination performance and fast dissolving speed of the powdered soap, and has special efficacy of depilation. The animal depilating powdered soap is mainly used for removing clothing hair before operation on animals.
OBJECTIVES: In this study, we aimed to compare the maternal and neonatal outcomes in pregnant women diagnosed with idiopathic thrombocytopenic purpura (ITP) in our clinic between different platelet groups.
METHODS: This study was designed retrospectively. A total of 62 pregnant women with ITP were included in the study. Demographic and clinical data for all cases were evaluated. Perinatal outcomes were evaluated according to platelet counts.
RESULTS: The median age of the patients participating in the study was 27, and their ages ranged from 21 to 44. ITP was diagnosed before pregnancy in 32.3 % (n=20) of the patients and during pregnancy in 67.7 % (n=42). The average platelet counts of the patients during the first trimester and birth were 104.8/μL (15-168) and 84/μL (16-235), respectively. The average platelet count of newborns is 242/μL. The most common (74.2 %) ITP treatment method is the combination of steroids and IVIG. The platelet count of 80.6 % of newborns is above 151/μL. There was no statistical difference between the results of both mothers and fetuses when the groups were categorized according to maternal platelet levels.
CONCLUSIONS: In this study, no difference was observed in maternal and neonatal morbidity and mortality rates, despite the different platelet counts of patients with ITP. The cooperation of the hematology, gynecology, obstetrics, and neonatology departments is responsible for this.
The invention belongs to the field of ethnic minority medicines and discloses a Yao medicine composition for treating pains in waists and lower extremities and a preparation method thereof. The composition comprises 2-20 parts by weight of sabia fasciculata Lec. ex L. Chen, 3-30 parts by weight of spayholobus suberectus Dunn, 2-20 parts by weight of bauhinia championii (Benth) Benth., 2-20 parts by weight of psychotria serpens L. and 3-30 parts by weight of luffa cylindrica (L.) Roem. The dosage form of the composition is powder, tea bags or medicinal liquor. The preparation method comprises the processes of grinding, baking and sterilizing the raw medicines, thus preparing the powder, tea bags or medicinal liquor. Clinical tests show that the Yao medicine composition has the functions of dispelling the wind and eliminating dampness, promoting blood circulation to remove blood stasis, relaxing tendons and activating collaterals, relieving swelling and pains, activating and replenishing blood, strengthening the spleen and the stomach and strengthening tendons and muscles, improves the body resistance and relaxes tendons and activates the collaterals, thus achieving the effects of health protection and treatment of the pains in waists and lower extremities; the Yao medicine composition takes effect quickly, has stable curative effects and no toxic or side effect and is a health protection medicine with preventive and therapeutic effects on the pains in waists and lower extremities.
The outbreak of infectious diseases often exhibits periodicity, and this periodic behavior can be mathematically represented as a limit cycle. However, the periodic behavior has rarely been considered in demonstrating the cluster phenomenon of infection induced by diffusion (the instability modes) in the SIR model. We investigate the emergence of Turing instability from a stable equilibrium and a limit cycle to illustrate the dynamical and biological mechanisms of pattern formation. We identify the Hopf bifurcation to demonstrate the existence of a stable limit cycle using First Lyapunov coefficient in our spatiotemporal diffusion-driven SIR model. The competition between different instability modes induces different types of patterns and eventually spot patterns emerge as stable patterns. We investigate the impact of susceptible, infected, and recovered individuals on the type of patterns. Interestingly, these instability modes play a vital role in selecting the pattern formations, which is directly related to the number of observed spot patterns. Subsequently, we explain the dynamical and biological mechanisms of spot patterns to develop an effective epidemic prevention strategy.
Childhood obesity is the most serious public health problem of the 21st century, given the prevalence, global reach, and widespread health, economic, and social consequences. While weight gain at the most basic level is due to a chronic energy surplus, there are a host of influences that act on the energy balance system that remain largely unknown. Thus, there is a critical need to identify previously unexamined factors that may influence the energy balance system in order to develop effective interventions for prevention and treatment. Our long-term goal is to quantify the dynamic relationships between various physiological and psychological components of the energy balance system. Our short-term goal is to examine linkages between physical activity, appetite control, and energy metabolism in adolescents. The status quo as it relates to appetite control is that body weight status and related peripheral signals are a key regulator of energy intake. In contrast to body weight playing a primary role in energy regulation, our working hypothesis is that high levels of regular moderate-to-vigorous physical activity (MVPA) result in a metabolic phenotype consisting of enhanced metabolic function and proper regulation of appetite, which prevents the development of obesity. The investigators have reported that adults with low levels of MVPA have dysregulated appetite control, evidenced by higher levels of energy intake and elevated levels of dietary disinhibition. Additionally, the investigators have observed that rats with low fitness possess dysregulated control of appetite and reduced hepatic fat oxidation compared to rats with high fitness. Based on these findings in adults and rodents, in addition to supportive work by others, the investigators hypothesize that low levels of MVPA create a metabolic phenotype, leading to dysregulated appetite control which predisposes individuals to weight gain. To test this hypothesis the investigators will perform a study focused on the links between physical activity and appetite. The investigators will assess metabolic function and appetite control in male and female adolescents stratified by bodyweight (normal vs overweight/obese) and physical activity (sedentary vs. active) using a 2 x 2 cross-sectional study design (N=44). The specific aim of the proposed study is: 1) To examine the association between physical activity and appetite control in adolescents, with metabolic function serving as a mediator. At the completion of the study, it is our expectation that the investigators will have described the independent effects of physical activity and body weight on energy metabolism and appetite in adolescents. This study will have a significant positive impact on the understanding of energy balance in adolescents, and will inform public health interventions that specifically target mechanisms associated with weight gain in youth.
4-(2-(Benzene sulphonamido)ethyl) phenoxy-acetic acid is made by reacting N-(2-(4-halo phenyl) ethyl)benzene sulphonamide in which halo is fluoro, chloro, bromo or iodo, with an alkali metal (Li, Na or K) salt of 2-hydroxy acetic acid in a suitable solvent and isolating the prod. by conventional means. The reactants are used in equimolar mounts, an organic solvent is used and the reaction may be catalysed by copper salts e.g. cuprous chloride. Reaction is at between 60 deg. C and reflux temp. and the prod. is recrystallised from organic solvent e.g. ethanol.
CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using behavioral health services. Individuals then select "True" or "False" in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced. Participants in this condition will complete three separate 15-minute CBM-HS sessions.
The study is investigating the use of transcranial alternating current stimulation (tACS). For the experimental arm, the stimulation is delivered at 2 milliamperes (mA) with the stimulation electrode over the left prefrontal cortex (F3) and left orbitofrontal cortex (Fp1) using the cross-frequency stimulation waveform theta-gamma.
A glucose level control system may be configured to adapt a time-segmented basal dose. The glucose level control system may determine the first basal dose based at least in part on a user-specified basal dose and/or total daily dose value. The first basal dose may also be based on a basal dose received from the memory of the glucose level control system or from a remote storage device. The first basal dose may be administered during a first time period. The glucose level control system may adapt the first basal dose to a second basal dose for a second therapy period. The glucose level control system may adapt the second basal dose based on a difference between a predicted and measured glucose level.
A system for providing an interface with activity recommendations by monitoring user activities in which user data relating to a user is received at a user device is described. The user data includes at least image data, text input, biometric data, and audio data, and may have been captured using one or more sensors on the user device. Processing the user data using at least: analyzing the face; a physical analysis; eye tracking; analyzing voice; analyzing the behaviors; analyzing the social network; positioning and analyzing; analyzing the activity of the user; and text analysis. Based on the user data, one or more states of one or more cognitive affective capabilities of the user can be determined. Determining an emotional characteristic of the user based on the one or more states of the one or more cognitive affective capabilities of the user. Based on the emotional feature, one or more recommendations for improving the emotional feature may be recommended.
The present invention relates to skin care compositions in the form of solid sticks for maintaining and improving the condition of the skin, especially redness in the areas under an absorbent article. The skin care stick provides an efficient and aesthetically pleasing delivery vehicle for topically applying a very low level of the skin care composition to the skin and achieving efficacy. The stick composition has a desired hardness so as to maintain dimensional stability and is capable of depositing a very small but effective amount of the skin care composition onto the skin during use. The present invention also relates to methods of improving the skin condition, especially the redness associated with chronic exposure of the skin to body waste, moisture, irritants, etc. The method comprises applying a thin layer of a skin care composition in the stick form and achieving efficacy at a very low level of application. The present invention further relates to methods for manufacturing the skin care stick compositions of the present invention.
There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
<P>PROBLEM TO BE SOLVED: To provide a method for culturing neural stem cells, which increases cell proliferation rate, increases neuron counts in a differentiated cell population, and modifies the survival degree of stem cell implants in making transplantation to a host.  <P>SOLUTION: New human stem cells having a doubling rate of 5-10 days are provided. New human CNS neural stem cells including a standard proliferating medium for extending the proliferation of human neural stem cells are also provided. Further, a method for proliferating, differentiating and transplanting the above human CNS neural stem cells is provided. The cell culture medium includes the standard proliferating medium, effective amounts of one or more growth factors such as LIF stimulating the neural stem cell proliferation.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. The peptides of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors expressing IMP-3.
The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
PURPOSE:To provide the titled lotion having excellent wave-forming and wave- retaining properties and giving little damage to the hair, by adding abietic acid or rosin, etc. to at least one of the first liquid containing thioglycolic acid salt or cysteine and the second liquid containing a bromic acid salt. CONSTITUTION:An excellent two-pack permanent wave lotion is obtained by adding >=0.1wt% (preferably 1-20wt%) of abietic acid or rosin or their salt (e.g. alkali metal salt, organic base salt, etc.) or derivative (e.g. ester, amide, etc.) to one or both of the first liquid containing thioglycolic acid salt or cysteine as a main component and the second liquid containing a bromic acid salt as a main component. In the case of the one-pack lotion, the treatment of the hair can be carried out only by applying the lotion to the hair and exposing to air.
Recent clinical reports from multiple pediatric cardiology programs around the world indicate that the conduit can be repaired using such a stent. In the United States there are no commercially available, FDA approved, covered stents of the size required. The Covered Cheatham Platinum Stent (CCPS) manufactured by the NuMED Corporation of Hopkinton, New York has been used in Europe since 2003 and more recently in Canada. The CCPS device is not yet approved by the Food \& Drug Administration (FDA). However, it has been used at many hospitals in the U.S. to repair Right Ventricle to pulmonary artery conduits under Emergency and Compassionate Use circumstances. The NuMED Covered Cheatham-Platinum Stent (CCPS) is currently being studied for use in other areas of the body. The investigators are now studying its use in RV-PA conduits. The use of the Covered Cheatham Platinum Stent in this research study is investigational.

Only patients found to have a conduit tear during a Melody Valve implant procedure will be eligible for inclusion into the trial. Implant technique is left to the catheterization physician. Clinical data obtained during the catheterization, before and after the CCPS implant will be studied in order to understand factors leading up to the tear and to evaluate how successful the CCPS is in repairing such defects. Melody valve implant patients are routinely seen for clinical and echocardiographic reevaluation 6 months after implant. Patients who have received a CCPS during their Melody valve procedure will likewise be seen. Results from their clinical evaluation will be reviewed to make sure that the presence of a CCPS does not diminish the effectiveness of the Melody valve. Finally, the catheterization angiograms and 6 month follow up echocardiograms will be reviewed by an independent expert to confirm the clinical readings.
Heme serves as a prosthetic group in hemoproteins, including subunits of the mammalian mitochondrial electron transfer chain. The first enzyme in vertebrate heme biosynthesis, 5-aminolevulinic acid synthase 1 (ALAS1), is ubiquitously expressed and essential for producing 5-aminolevulinic acid (ALA). We previously showed that Alas1 heterozygous mice at 20-35 weeks (aged-A1+/-s) manifested impaired glucose metabolism, mitochondrial malformation in skeletal muscle, and reduced exercise tolerance, potentially linked to autophagy dysfunction. In this study, we investigated autophagy in A1+/-s and a sarcopenic phenotype in A1+/-s at 75-95 weeks (senile-A1+/-s). Senile-A1+/-s exhibited significantly reduced body and gastrocnemius muscle weight, and muscle strength, indicating an accelerated sarcopenic phenotype. Decreases in total LC3 and LC3-II protein and Map1lc3a mRNA levels were observed in aged-A1+/-s under fasting conditions and in Alas1 knockdown myocyte-differentiated C2C12 cells (A1KD-C2C12s) cultured in high- or low-glucose medium. ALA treatment largely reversed these declines. Reduced AMP-activated protein kinase (AMPK) signaling was associated with decreased autophagy in aged-A1+/-s and A1KD-C2C12s. AMPK modulation using AICAR (activator) and dorsomorphin (inhibitor) affected LC3 protein levels in an AMPK-dependent manner. Our findings suggest that heme deficiency contributes to accelerated sarcopenia-like defects and reduced autophagy in skeletal muscle, primarily due to decreased AMPK signaling.
All subjects who are randomized to Caplyta will receive 42mg/day starting the first week of the study. Subjects will be seen every two weeks for 8 weeks. Dosage changes and reductions will not be permitted. After study conclusion (week 8), the dose will be discontinued.
ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
Previous studies have shown that podocyte injury is involved in the development of proteinuria in rats under hypobaric hypoxia conditions. Prolyl hydroxylase inhibitors (PHIs) may reduce proteinuria. This study aimed to further investigate whether the protective effects of hypoxia-inducible factor 1α (HIF1α) on podocyte injury induced by hypobaric hypoxia are related to Krüppel-like factor 4 (KLF4). Rats were housed in a low-pressure oxygen chamber to simulate a high-altitude environment (5000 m), and a PHI was intraperitoneally injected. Urinary protein electrophoresis was performed and the morphology of the podocytes was observed by electron microscopy. Rat podocytes were cultured under 1% O2, and siRNA was used to interfere with KLF4 expression. The protein expression levels of HIF1α, KLF4, CD2-associated protein (CD2AP) and nephrin were determined by western blotting. Compared with those in the experimental group, the rats in the intervention group on day 14 had lower urinary protein levels, increased protein expression levels of CD2AP and nephrin, and reduced podocyte injury. The results of in vitro experiments showed that the protein expression levels of KLF4, CD2AP and nephrin were greater in the PHI intervention group and lower in the HIF1α inhibitors group than in the low-oxygen group. The protein expression of CD2AP and nephrin in the siKLF4-transfected podocytes treated with PHI and HIF1α inhibitors did not differ significantly from that in the low-oxygen group. HIF1α may be involved in reducing progressive high-altitude proteinuria by regulating KLF4 expression and contributing to the repair of podocyte injury induced by hypobaric hypoxia.
The mechanical properties of solid pharmaceutical excipients are important for assisting drug tables production, and they determine the quality of the drug tablets. The purpose of this study was to explore the potential and mechanism of crystal defect engineering to improve the mechanical properties of Mannitol@CaCl2 MOF, a pharmaceutical excipient with metal-organic framework (MOF) structure designed and prepared in our previous study. In this study, a simple and efficient "induced dehydration strategy" was proposed to prepare Mannitol@CaCl2 MOF with crystal defects (DEMOF). SEM, TEM, HRTEM, PXRD, FTIR, DSC-TGA, and N2 adsorption-desorption isotherm revealed the successful introduction of lattice vacancy and macrostructural defects while preserving MOF's skeleton structure. Tabletability profiles indicated that DEMOF presented much better mechanical properties than the original MOF at the powder level. On single crystal and atomic scales, nanoindentation and DFT calculations revealed that the defect structure increased plasticity, decreased brittleness, and improved compressibility, resulting in DEMOF tablets with much higher tensile strength that met the criteria for direct compression excipients. The achieved performance modification illustrated the capability of defect engineering to tune mechanical properties of MOFs, and the Mannitol@CaCl2 DEMOF exhibited great potential to serve as a new direct compression pharmaceutical excipient.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to physiotherapy. Method includes carrying out sparing motor mode, diet nutrition, sea bathing. Area of affected joints is subjected to impact of darsonvalisation from apparatus "Iskra-1". Impact is performed by alternating current with frequency 110 Hz, modulated in series of bell-like shape, duration 100 mcs, following with frequency 50 Hz, with voltage on electrode 25-30 kV, at average power and sensation by patient of temperate warmth under electrode. Impact is performed in contact, labial manner for 10-15 minutes. 15-20 minutes after said procedure, sea weed from Anapa region are applied on the area of the same joints. Thickness of application is 5-6 cm. Temperature of applications is gradually reduced. During first three procedures it constitutes 40-42C, during 4-5 procedures 38-40C, during 6-7 procedures 36-38C, and during 8-10 procedures 34-36C. Time of impact is 20-25 minutes. 10 procedures per course, carried out after 1-2 days. ^ EFFECT: method increases duration of remission, increases efficiency of resort treatment of said category of patients and their life quality. ^ 2 ex